h1

h2

h3

h4

h5
h6
 
  1. Shih LY, Kuo MC, Liang DC. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003; 98(6):1206-1216.
  2. Zhang Y, Zhang Z, Li J. Long-term efficacy and safety of arsenic trioxide for firstline treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013; 119(1):115-125.
  3. Pantic M, Novak A, Marisavljevic D. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol. 2000; 17(4):307-313.
  4. Lucena-Araujo AR, Kim HT, Jacomo RH. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline- based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014; 93(12):2001-2010.
  5. Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016; 95(5):673-680.
  6. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-346.
  7. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. 1995.
  8. Burnett AK, Russell NH, Hills RK. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13):1295-1305.
  9. Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014; 27(1):3-9.
  10. Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018; 32(2):89-95.
  11. Kiguchi T, Yoshino Y, Yuan B. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 2010; 34(3):403-405.
  12. Lou Y, Suo S, Tong H. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leuk Res. 2013; 37(11):1451-1456.
  13. Rahmé R, Thomas X, Recher C. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014; 28(12):2422-2424.
  14. Cicconi L, Divona M, Ciardi C. PMLRARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016; 30(10):1987-1992.
  15. Lehmann S, Deneberg S, Antunovic P. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017; 31(6):1457-1459.
  16. Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018; 32(6):1277-1294.
  17. Kayser S, Rahmé R, Martínez-Cuadrón D. Outcome of older (70 years) APL patients frontline treated with or without arsenic trioxide- an International Collaborative Study. Leukemia. 2020; 34(9):2333-2341.
  18. Kiyoi H, Naoe T, Yokota S. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11(9):1447-1452.
  19. Yokota S, Kiyoi H, Nakao M. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997; 11(10):1605-1609.
  20. Noguera NI, Breccia M, Divona M. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002; 16(11):2185-2189.
  21. Schlenk RF, Germing U, Hartmann F. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005; 19(6):978-983.
  22. Davison K, Mann KK, Miller WH, Davison K. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002; 39(2 Suppl 1):3-7.
  23. Lo-Coco F, Avvisati G, Vignetti M. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-121.
  24. Hu J, Liu YF, Wu CF. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106(9):3342-3347.
  25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.
  26. Paulson K, Serebrin A, Lambert P. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014; 166(5):660-666.
  27. De Botton S, Chevret S, Sanz M. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000; 111(3):801-806.
  28. Pagano L, Pulsoni A. Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Blood. 2002; 100(4):1514-1515.
  29. de la Serna J, Montesinos P, Vellenga E. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with alltrans retinoic acid and idarubicin. Blood. 2008; 11(7):3395-4302.
  30. Powell BL, Moser B, Stock W. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116(19):3751-3757.
  31. Lo-Coco F, Avvisati G, Vignetti M. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA- 2000 trial of the GIMEMA group. Blood. 2010; 116(17):3171-3179.
  32. Park JH, Qiao B, Panageas KS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011; 118(5):1248-1254.
  33. Zhu H, Hu J, Chen L. The 12-year follow- up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016; 128(11):1525-1528.
  34. Sanz MA, Fenaux P, Tallman MS. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019; 133(15):1630-1643.
  35. Thiede C, Steudel C, Mohr B. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12):4326-4335.
  36. Cheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
  37. Montesinos P, González JD, González J. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol. 2010; 28(24):3872-3879.
  38. Ghavamzadeh A, Alimoghaddam K, Rostami S. Phase II study of singleagent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29(20):2753-2757.
  39. Platzbecker U, Avvisati G, Cicconi L. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2016; 35(6):605-612.
  40. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16(3):1141-1154.
  41. Poiré X, Moser BK, Gallagher RE. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014; 55(7):1523-1532.
  42. Cervera J, Montesinos P, Hernández-Rivas JM. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010; 95(3):424-431.
  43. Noguera NI, Catalano G, Banella C. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers. 2019; 11(10):1591.
  44. Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-625.
  45. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2014.
  46. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. 2017.
Similar records